Trial Profile
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2012
Price :
$35
*
At a glance
- Drugs Linezolid (Primary)
- Indications Vancomycin-resistant enterococcal infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 29 Jun 2012 Actual patient number changed from 15 to 41as reported by ClinicalTrials.gov.
- 06 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.